CELCUITY INC (CELC:NASDAQ)
$83.56 -1.93 (-2.2576%)
Analysed CELCUITY INC (CELC:NASDAQ) News Sources
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
30-07-2026
yahoo.com
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
06-08-2026
yahoo.com
Celcuity Q2 Earnings Call Highlights
13-08-2026
marketbeat.com
Celcuity Inc (CELC) (Q2 2026) Earnings Call Highlights: FDA Approval and Commercial Launch ...
14-08-2026
yahoo.com
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss
16-08-2026
yahoo.com
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch?
16-08-2026
yahoo.com
Celcuity (CELC) Q2 2026 Earnings Call Transcript
20-08-2026
fool.com
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
26-08-2026
yahoo.com
Celcuity (CELC): Landmark Approval Collides With A Costly Launch
27-08-2026
yahoo.com
Celcuity To Participate in Upcoming Investor Conferences
01-09-2026
yahoo.com
What is the current price of CELCUITY INC (CELC:NASDAQ)?
The current price of CELCUITY INC (CELC:NASDAQ) is $83.56.
CELCUITY INC (CELC:NASDAQ) absolute price change since previous trading day?
The absolute price change of CELCUITY INC (CELC:NASDAQ) since the previous trading day is $-1.93.
CELCUITY INC (CELC:NASDAQ) percentage price change since previous trading day?
The percentage price change of CELCUITY INC (CELC:NASDAQ) since the previous trading day is -2.2576%.
What is the most recent average sentiment score for CELCUITY INC (CELC:NASDAQ)?
The most recent average sentiment score for CELCUITY INC (CELC:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for CELCUITY INC (CELC:NASDAQ)?
The most recent sentiment for CELCUITY INC (CELC:NASDAQ) is .
SEC-8K** Filing Available For CELCUITY INC (CELC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.